Download PDF
Dtsch Med Wochenschr 2012; 137(04): 143-148
DOI: 10.1055/s-0031-1298814
Übersicht | Review article
Nephrologie
© Georg Thieme Verlag KG Stuttgart · New York

Nephrologische Nebenwirkungen einer Langzeittherapie mit Lithium

Renal side effects of long-term lithium therapy
C. Ibbeken
1   1. Medizinische Klinik, St. Franziskus Hospital Münster
,
J. U. Becker
2   Institut für Pathologie, Medizinische Hochschule Hannover
,
M. W. Baumgärtel
1   1. Medizinische Klinik, St. Franziskus Hospital Münster
› Author Affiliations
Further Information

Publication History

20 June 2011

14 September 2011

Publication Date:
18 January 2012 (online)

Also available at
    Permissions and Reprints

Zusammenfassung

Lithium-Salze sind Therapie der ersten Wahl in der Phasenprophylaxe bipolarer Störungen. Die Langzeittherapie geht häufig mit Nebenwirkungen einher, welche die Fachgebiete der Nephrologie, der Endokrinologie und der endokrinen Chirurgie berühren. In dieser Übersichtsarbeit werden nephrologische Nebenwirkungen hervorgehoben.

Unter Behandlung mit Lithium wird das gehäufte Auftreten einer Resistenz gegen das antidiuretische Hormon (ADH) mit nephrogenem Diabetes insipidus, ein Lithium-getriggerter Hyperparathyreoidismus mit Hyperkalzämie und eine chronisch-interstitielle Nephritis mit der Bildung von Mikrozysten beobachtet. Langzeit-Patienten haben ein erhöhtes Risiko für die Entwicklung einer chronischen Niereninsuffizienz. Selten kommt es auch zur Dialyse-Abhängigkeit. Die rechtzeitige Beendigung der Lithium-Therapie scheint dies verhindern zu können.

Um die Sicherheit einer Lithium-Therapie zu gewährleisten sind regelmäßige Bestimmungen des Serum-Lithium-Spiegels, Kontrollen der Retentionsparameter, des Spiegels des Thyreoidea stimulierenden Hormons (TSH) und des Kalzium-Spiegels sowie der Urin-Osmolarität essenziell. Rechtzeitig –  also bereits bei einem leichten Anstieg der Retentionsparameter – sollte eine nephrologische bzw. internistische Vorstellung erfolgen.

Abstract

Lithium is widely used in the treatment of bipolar disorders. Long-term administration of lithium often leads to side effects concerning the subjects: nephrology, endocrinology and surgery. This review emphasizes nephrotoxicity.

Lithium treatment may disturb responsiveness to antidiuretic hormone (ADH), causing a nephrogenic diabetes insipidus. Furthermore long-term lithium therapy may trigger hyperparathyreoidism with hypercalcemia and chronic interstitial nephritis with development of microcysts. Long-term patients have an increased risk to develop impaired renal function. Lithium-induced endstage renal disease is rare. Termination of lithium treatment may decrease the risk of progression.

To ensure security of lithium treatment regular controls of urine osmolarity, lithium-, creatinine- , thyroid stimulating hormone- and calcium-levels are essential. Patients with decreased renal function should be referred to a specialist early.

Schlüsselwörter

Lithium - Nephropathie - Mikrozysten - nephrogener Diabetes insipidus - Hyperparathyreoidismus - Nierenfunktion

Keywords

lithium - nephropathy - microcysts - Diabetes insipidus renalis - hyperparathyreoidism - renal function
 

  • Literatur

  • 1 Bassilios N, Martel P, Godard V et al. Monitoring of glomerular filtrating rate in lithium-treated outpatients – an ambulatory laboratory database surveillance. Nephrol Dial Transplant 2008; 23: 562-565
    PubMedGoogle Scholar
  • 2 Bedford JJ, Weggery S, Ellis G et al. Lithium-induced Nephrogenic Diabetes insipidus: Renal Effects of Amiloride. Clin J Am Soc Nephrol 2008; 3: 1324-1331
    CrossrefPubMedGoogle Scholar
  • 3 Bendz H, Aurell M, Lanke J. A historical cohort study of kidney damage in long-term lithium patients: continued surveillance needed. Eur Psychiatry 2001; 16: 199-206
    CrossrefPubMedGoogle Scholar
  • 4 Bendz H, Schön S, Attman PO et al. Renal failure occurs in chronic lithium treatment but is uncommon. Kidney International 2009; 77: 219-224
    PubMedGoogle Scholar
  • 5 Bendz H, Sjödin I, Toss G et al. Hyperparathyroidism and longterm lithium therapy – A cross-sectional study and the effect of lithium withdrawal. J Intern Med 1996; 240: 357-365
    CrossrefPubMedGoogle Scholar
  • 6 Boton R, Gaviria M, Batlle DC. Prevalence, pathogenesis, and treatment of renal dysfunction associated with chronic lithiumtherapy. Am J Kidney Dis 1987; 10: 329-345
    PubMedGoogle Scholar
  • 7 Christensen BM, Marples D, Kim YH et al. Changes in cellular composition of kidney collecting duct cells in rats with lithium-induced NDI. Am J Physiol Cell Physiol 2004; 286: 952-964
    CrossrefPubMedGoogle Scholar
  • 8 Christensen BM, Zuber AM, Loffing J et al. alphaENaC-mediated lithium absorption promotes nephrogenic diabetes insipidus. J Am Soc Nephrol 2011; 22: 253-261
    CrossrefPubMedGoogle Scholar
  • 9 Christiansen C, Baastrup PC, Lindgreen P et al. Endocrine effects of lithium: II. 'Primary' hyperparathyroidism. Acta Endocrinol (Copenh) 1978; 88: 528-534
    PubMedGoogle Scholar
  • 10 Farres MT, Ronco P, Saadoun D et al. Chronic Lithium Nephropathie: MR Imaging for diagnosis. Radiology 2003; 229: 570-574
    CrossrefPubMedGoogle Scholar
  • 11 Finley PR, Warner MD, Peabody CA. Clinical relevance of drug interactions with lithium. Clin Pharmacokinet 1995; 29: 172-191
    CrossrefPubMedGoogle Scholar
  • 12 Freeman MP, Freeman SA. Lithium: clinical considerations in internal medicine. Am J Med 2006; 119: 478-481
    CrossrefPubMedGoogle Scholar
  • 13 Frew IJ, Thoma CR, Greorgiev S et al. pVHL an PTEN tumor suppressor proteins cooperatively suppress kidney cyst formation. EMBO J 2008; 27: 1747-1757
    CrossrefPubMedGoogle Scholar
  • 14 Garfinkel PE, Ezrin C, Stancer HC. Hypothyroidism and hyperparathyroidism associated with lithium. Lancet 1973; 2: 331-332
    CrossrefPubMedGoogle Scholar
  • 15 Gregoor PS, de Jong GM. Lithium hypercalcemia, hyperparathyroidism, and cinacalcet. Kidney Int 2007; 71: 470
    CrossrefPubMedGoogle Scholar
  • 16 Grünfeld JP, Rossier BC. Lithium nephrotoxicity revisited. Nat Rev Nephrol 2009; 5: 270-276
    CrossrefPubMedGoogle Scholar
  • 17 Handler J. Lithium and antihypertensice medication: a potentially dangerous interaction. J Clin Hypertens (Greenwich) 2009; 11: 738-42
    CrossrefPubMedGoogle Scholar
  • 18 Hestbech J, Hansen HE, Amdisen A et al. Chronic renal lesions following long-term treatment with lithium. Kidney Int 1977; 12: 205-213
    CrossrefPubMedGoogle Scholar
  • 19 Hoffert JD, Pisitkun T, Wang G et al. Quantitative phosphoproteomics of vasopressin-sensitive renal cells: regulation of aquaporin-2 phosphorylation at two sites. Proc Natl Acad Sci USA 2006; 103: 7159-7164
    CrossrefPubMedGoogle Scholar
  • 20 Hundley JC, Woodrum DT, Saunders BD et al. Revisiting lithium-associated hyperparathyroidism in the era of intraoperative parathyroid hormone monitoring. Surgery 2005; 138: 1027-1031
    CrossrefPubMedGoogle Scholar
  • 21 Janowsky DS, Soares J, Hatch JP et al. Lithium effect on renal glomerular function in individuals with intellectual disability. J Clin Psychopharmacol 2009; 29: 296-299
    CrossrefPubMedGoogle Scholar
  • 22 Kortenoeven ML, Li Y, Shaw S et al. Amiloride blocks lithium entry through the sodium channel thereby attenuating the resultant nephrogenic diabetes insipidus. Kidney Int 2009; 76: 44-53
    CrossrefPubMedGoogle Scholar
  • 23 Kwon TH, Laursen UH, Marples D et al. Altered expression of renal AQPs and Na-transporters in rats with lithium-induced NDI. Am J Physiol Renal Physiol 2000; 279: 552-564
    PubMedGoogle Scholar
  • 24 Laursen UH, Pihaskaski-Maunsbach K, Kwon TH et al. Changes of rat kidney AQP2, and Na, K-ATPase mRNA expression in lithium-induced nephrogenic diabetes insipidus. Nephron Exp Nephrol 2004; 97: 1-16
    CrossrefPubMedGoogle Scholar
  • 25 Markowitz GS, Radhakrishnan J, Kambham N et al. Lithium nephrotoxicity: a progressive combined glomerular and tubulointerstitial nephropathy. J Am Soc Nephrol 2000; 11: 1439-1448
    PubMedGoogle Scholar
  • 26 McCann SM, Daly J, Kelly CB. The impact of long-term lithium treatment on renal function in an outpatient population. Ulster Med J 2008; 77: 102-105
    PubMedGoogle Scholar
  • 27 Nielsen J, Kwon TH, Frøkiaer J et al. Lithium-induced NDI in rats is associated with loss of alpha-ENaC regulation by aldosterone in CCD. Am J Physiol Renal Physiol 2006; 290: 1222-1233
    PubMedGoogle Scholar
  • 28 Nielsen J, Kwon TH, Praetorius J et al. Segment-specific ENaC downregulation in kidney of rats with lithium-induced NDI. Am J Physiol Renal Physiol 2003; 285: 1198-1209
    PubMedGoogle Scholar
  • 29 Presne C, Fakhouri F, Noël LH et al. Lithium-induced nephropathy: rate of progression and prognostic factors. Kidney Int 2003; 64: 585-592
    CrossrefPubMedGoogle Scholar
  • 30 Rao R, Zhang MZ, Zhao M et al. Lithium treatment inhibits renal GSK-3 activity and promotes cyclooxygenase 2-dependent polyuria. Am J Physiol Renal Physiol 2005; 288: 642-649
    PubMedGoogle Scholar
  • 31 Rifai MA, Moles JK, Harrington DP. Lithium-induced hypercalcemia and parathyroid dysfunction. Psychosomatics 2001; 42: 359-361
    CrossrefPubMedGoogle Scholar
  • 32 Robben JH, Knoers NV, Deen PM. Cell biological aspects of the vasopressin type-2 receptor and aquaporin 2 water channel in nephrogenic diabetes insipidus. Am J Physiol Renal Physiol 2006; 291: 257-270
    CrossrefPubMedGoogle Scholar
  • 33 Sloand JA, Shelly MA. Normalization of lithium-induced hypercalcemia and hyperparathyroidism with cinacalcet hydrochloride. Am J Kidney Dis 2006; 48: 832-837
    CrossrefPubMedGoogle Scholar
  • 34 Stone KA. Lithium-induced nephrogenic diabetes insipidus. J Am Board Fam Pract 1999; 12: 43-47
    PubMedGoogle Scholar
  • 35 Thoma CR, Frew IJ, Hoerner CR et al. pVHL and GSKbeta are components of primary cilium-maintenance signalling network. Nat Cell Biol 2007; 9: 588-595
    CrossrefPubMedGoogle Scholar
  • 36 Thoma CR, Frew IJ, Krek W. The VHL tumor suppressor: riding tandem with GSK3beta in primary cilium maintenance. Cell Cycle 2007; 6: 1809-1813
    CrossrefPubMedGoogle Scholar
  • 37 Tredget J, Kirov A, Kirov G. Effects of chronic lithium treatment on renal function. J Affect Disord 2010; 126: 436-440
    CrossrefPubMedGoogle Scholar
  • 38 Tuazon J, Casalino D, Syed E et al. Lithium-associated kidney microcysts. ScientificWorldJournal 2008; 31: 828-829
    PubMedGoogle Scholar
  • 39 Wada A. Lithium and neuropychiatric therapeutics: neuroplasticitiy via glycogen synthethase kinase-3, -catenin, and neurotropin cascades. J Parmacol Sci 2009; 110: 14-28
    PubMedGoogle Scholar
  • 40 Waring WS. Management of Lithium toxicity. Toxicol Rev 2006; 25: 221-230
    CrossrefPubMedGoogle Scholar
  • 41 Wilting I, Egberts AC, Heerdink ER et al. Evaluation of available treatment guidelines fort he management of lithium intoxication. Ther Drug Monit 2009; 31: 247-260
    CrossrefPubMedGoogle Scholar